Form 4: Milestone Pharmaceuticals CFO Amit Hasija Granted Stock Options and Restricted Stock Units
SEC Form 4 Filing
Amit Hasija, CFO & EVP of Corporate Development at Milestone Pharmaceuticals, received stock options and restricted stock units on January 27, 2025, according to a Form 4 filing.
Summary
- Amit Hasija, the CFO & EVP of Corporate Development at Milestone Pharmaceuticals Inc., was granted employee stock options and restricted stock units on January 27, 2025.
- The stock options grant covers 120,600 common shares with an exercise price of $2.02 per share.
- These options vest over time, with one-fourth vesting on January 27, 2026, and the remaining shares vesting monthly thereafter, contingent upon continued service.
- Hasija also received 80,400 restricted stock units, each representing a contingent right to receive one common share.
- These restricted stock units vest in equal installments on January 27th of 2026, 2027, 2028, and 2029, also subject to continued service.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to slightly positive.
Positives
- The granting of stock options and restricted stock units aligns the CFO's interests with those of the shareholders.
- The vesting schedule incentivizes continued service and commitment to the company's long-term success.
Risks
- The value of the stock options and restricted stock units is dependent on the future performance of Milestone Pharmaceuticals' stock price.
- If Hasija leaves the company before the vesting dates, he will forfeit the unvested options and restricted stock units.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.
Industry Context
Granting stock options and restricted stock units is a common practice in the pharmaceutical industry to attract, retain, and incentivize key executives.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
- Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options and restricted stock units to incentivize their executives.
- The vesting schedules are typical, designed to retain talent over a multi-year period.
Stakeholder Impact
- Shareholders may view the grants positively as they align management's interests with the company's performance.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/27/2025 | Date of transaction: Grant of stock options and restricted stock units. |
| 01/27/2026 | First vesting date for both stock options and restricted stock units. |
| 01/27/2027 | Second vesting date for restricted stock units. |
| 01/27/2028 | Third vesting date for restricted stock units. |
| 01/27/2029 | Final vesting date for restricted stock units. |
| 01/27/2035 | Expiration date for the employee stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.